Posts by Mourabit Halima

Editor’s Note At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the ANCHOR study, led by Professor Kefeng Ding from the Second Affiliated Hospital of Zhejiang University School of Medicine, was presented as a Late-Breaking Abstract (LBA), marking a significant breakthrough in the treatment landscape of advanced colorectal cancer.

Editor’s Note At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, three high-impact studies targeting KRAS G12C-mutant colorectal cancer (CRC) revealed groundbreaking progress in precision oncology. KRAS G12C is a notoriously difficult-to-treat molecular subtype of CRC, historically plagued by limited therapeutic options. However, the presentation of data from the CodeBreaK 101 study, a Phase I/II trial of olomorasib combined with cetuximab, and the KANDLELIT-001 trial has brought new hope to the field.

Editor’s Note: A deep understanding of the dynamic changes within the tumor microenvironment is crucial to accurately assess treatment response and disease progression in cancer patients. At the 2025 ASCO…

Nasopharyngeal carcinoma (NPC) is a malignancy with high prevalence in Southern China and other Southeast Asian countries, imposing a significant disease burden. Treatment options for recurrent/metastatic NPC (R/M NPC) remain limited. In recent years, immune checkpoint inhibitors (ICIs) have brought new hope to this patient population, and domestically developed ICIs in China have demonstrated promising efficacy.

In celebration of the 2025 National Science and Technology Workers Day and International Children’s Day, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College hosted a public science outreach event as part of the National Open Day at the National Key Laboratory of Hematology and Health. Over 200 primary and secondary school students from Tianjin, accompanied by their parents, participated in the event. The Deputy Director of Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Dr. Xiaoli Liu, delivered opening remarks, and the event was chaired by Mr. Chuan Wang, Director of the Education Office.

Editor’s Note: The 2025 ASCO Annual Meeting is currently in full swing across the Pacific, and several China-led clinical studies in breast cancer have captured significant international attention. Among them,…

Editor's Note: At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the ANCHOR study, led by Professor Kefeng Ding from The Second Affiliated Hospital Zhejiang University School of…

&t=47s

The 2025 ASCO Annual Meeting successfully concluded in Chicago on June 3( local time). Hengrui Pharma delivered a strong international presence, featuring 15 innovative drugs and 72 research outcomes. These included 4 oral presentations, 5 rapid oral presentations, 27 poster presentations, and 36 online publications. Multiple groundbreaking research advances has elicited widespread discussion among global experts.